Fig. 1 · Structure

Documents & Downloads

Cilofexor

Cat. No. A13143 CAS 1418274-28-8

FXR agonist

Cilofexor (GS-9674) is a farnesoid X receptor (FXR) agonist.

In Stock

Publications for Cilofexor

1 publication citing this product

  1. Caroline Klindt, .et al. , Am J Physiol Gastrointest Liver Physiol, 2024, Oct 1 PMID: 39350733

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Cilofexor is a nonsteroidal FXR agonist. In Cyp2c70 knockout mice, dietary cilofexor suppressed hepatic Cyp7a1 and increased Bsep expression, consistent with an FXR target-gene response. These in vivo findings do not establish an assay EC50 or exclusive intestinal activity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cilofexor Research Summary

This section summarizes 3 in vivo studies of Cilofexor from 3 published references.

Cilofexor In Vivo Studies

Two weeks of dietary cilofexor lowered serum ALT in male and female Cyp2c70 knockout mice. The response was mixed: cilofexor alone increased ductular CK19 staining and collagen-gene expression, while hepatic bile acid hydrophobicity did not significantly decline. Coadministration with the IBAT inhibitor SC-435 generally improved more injury endpoints than monotherapy. [1]

In a rat model of NASH-associated portal hypertension, ten weeks of dietary cilofexor produced a reported 25% decrease in portal pressure without changing mean arterial pressure, heart rate or mesenteric blood flow. Adding propranolol reduced mesenteric flow, but did not demonstrate synergistic portal-pressure lowering. [2]

In BALB/cJ Mdr2 knockout mice, ten weeks of daily cilofexor gavage reduced hepatic hydroxyproline at 10–90 mg/kg and picrosirius-red-positive area at 90 mg/kg. Serum AST, alkaline phosphatase and bilirubin improved at 90 mg/kg, while ALT and hepatic F4/80-positive area did not significantly improve. [3]

Short-term cilofexor and SC-435 treatment in cholestatic Cyp2c70 knockout mice

Animal study · Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age [1]

Dietary cilofexor lowered serum ALT in both sexes, suppressed hepatic Cyp7a1 and induced Bsep. Responses were mixed: cilofexor alone increased CK19-positive ductular cells and collagen-gene expression; lower Sirius Red staining did not establish uniform fibrosis reversal. Adding SC-435 generally improved more injury endpoints. Neither regimen significantly lowered hepatic bile acid hydrophobicity. These endpoints belong to one randomized-by-cage treatment design, not independent studies.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Serum ALT relative to chow-fed knockout micedirection Lower with cilofexor alone in both sexes[1]
Hepatic Cyp7a1 and Bsep mRNAdirection Cyp7a1 decreased; Bsep increased with cilofexor[1]
Ductular reaction, collagen expression and Sirius Red stainingdirection Cilofexor alone increased CK19-positive cells and Col1a1/Col1a2 expression; Sirius Red distributions were lower but no uniform monotherapy antifibrotic benefit established[1]
Calculated hydrophobicity of hepatic bile acidsdirection No significant reduction versus chow-fed knockout mice with cilofexor alone or combined with SC-435[1]

Conditions shared by the study groups

Route
Oral, in chow
Frequency
Ad libitum dietary exposure
Treatment course
2 weeks
Vehicle
Chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cilofexor alone
0.015% wt/wt; approximately 30 mg/kg/day
Chow-fed knockout mice; WT chow-fed littermates provide healthy referenceALT lower in both sexes; hepatic FXR target response; mixed histological and collagen-expression effects.[1]
Cilofexor plus SC-435
Cilofexor 0.015% plus SC-435 0.006% wt/wt (approximately 30 plus 11 mg/kg/day)
Knockout chow, cilofexor alone and SC-435 alone; WT referenceGenerally greater reductions in injury markers than monotherapy; hydrophobicity not significantly reduced. Combination benefit cannot be assigned to cilofexor alone.[1]
SC-435 comparator
0.006% wt/wt; approximately 11 mg/kg/day
Chow-fed knockout miceComparator reduced several injury endpoints; hepatic Cyp7a1 response differed from cilofexor.[1]
Cilofexor alone
Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
Cilofexor plus SC-435
Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
SC-435 comparator
Model: Male and female Cyp2c70 knockout mice on a C57BL/6J background, treatment from 12 to 14 weeks of age
Methods and source locations

Compound reported in the paper: Cilofexor; Compound label in the paper: Cilo

Compound-level mouse research; dietary exposure, not gavage; no salt conversion, potency or lot-validation claim.

Materials/Mouse Study and assay methods; Figures 1–5, 7–8; relevant Results and Discussion

Serum ALT relative to chow-fed knockout mice: Serum chemistry; boxplots show median, IQR, range and individual mice; no curve-derived numerical estimates. — Figure 1B–C; Results, Short-Term Treatment paragraph 2

Hepatic Cyp7a1 and Bsep mRNA: RT-qPCR normalized to cyclophilin D and expressed relative to WT; n = 7–8 mice/group; median, IQR and range. — Figures 4–5; Results, Differentially Regulates hepatic genes

Ductular reaction, collagen expression and Sirius Red staining: Whole-section QuPath quantification: histology n = 4–9 mice/group; gene expression n = 7–8; medians, IQR and range. No exact values inferred from plots. — Figures 2B–C and 3B–C; Results, Short-Term Treatment histology paragraph; Discussion, Short-Term Administration of Cilofexor

Calculated hydrophobicity of hepatic bile acids: Hepatic bile acid analysis; n = 7–8 mice/group; median, IQR and range. — Figures 7B and 8B; Results, Treatment-Induced Reduction in Liver Bile Acid Accumulation

Cilofexor alone · Materials/Mouse Study; Figures 1–5

Cilofexor plus SC-435 · Materials/Mouse Study; Figures 1–3, 7–8

SC-435 comparator · Materials/Mouse Study; Figures 1–5

Cilofexor with or without propranolol in NASH-associated portal hypertension

Animal study · Male Wistar rats in a 14-week choline-deficient high-fat diet/NaNO2 NASH model with portal hypertension [2]

In the independent 14-week cohort, dietary cilofexor reduced portal pressure without changing mean arterial pressure, heart rate or superior mesenteric artery blood flow. Propranolol reduced systemic pressure, heart rate and mesenteric flow; its portal-pressure reduction alone was a trend. Combination treatment reduced portal pressure and mesenteric flow, but did not show synergistic portal-pressure lowering.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Portal pressure with cilofexor alone versus untreated NASHreported relative decrease 25% decrease[2]
Mean arterial pressure, heart rate and superior mesenteric artery blood flowdirection Unchanged with cilofexor alone; no synergistic portal-pressure decrease with combination[2]

Conditions shared by the study groups

Route
Oral, incorporated into diet
Frequency
Dietary exposure; dose adjusted weekly
Treatment course
10 weeks (weeks 4–14)
Vehicle
Choline-deficient high-fat diet
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cilofexor alone (n = 9)
30 mg/kg
Untreated NASH rats (n = 9); healthy chow-fed controls (n = 9)Reported 25% lower portal pressure; systemic hemodynamics and mesenteric flow unchanged.[2]
Propranolol comparator (n = 7)
25 mg/kg propranolol
Untreated NASH rats; healthy referenceReduced mean arterial pressure, heart rate and mesenteric flow; portal-pressure reduction a trend (Figure 4c: p = 0.08).[2]
Cilofexor plus propranolol (n = 7)
30 mg/kg cilofexor plus 25 mg/kg propranolol
Untreated NASH and monotherapy groupsReduced portal pressure and mesenteric flow, with systemic pressure and heart-rate lowering resembling propranolol; no demonstrated portal-pressure synergy.[2]
Cilofexor alone (n = 9)
Model: Male Wistar rats in a 14-week choline-deficient high-fat diet/NaNO2 NASH model with portal hypertension
Propranolol comparator (n = 7)
Model: Male Wistar rats in a 14-week choline-deficient high-fat diet/NaNO2 NASH model with portal hypertension
Cilofexor plus propranolol (n = 7)
Model: Male Wistar rats in a 14-week choline-deficient high-fat diet/NaNO2 NASH model with portal hypertension
Methods and source locations

Compound reported in the paper: Cilofexor; Compound label in the paper: CILO

Compound-level rat hemodynamic effects for dietary exposure; no transfer to human treatment.

Sections 2.3–2.4, 2.8, 2.10, 3.3; Figure 4; Discussion

Portal pressure with cilofexor alone versus untreated NASH: Blinded invasive portal-pressure measurement at endpoint; n = 9 in cilofexor and NASH groups; figure mean ± SD. Percentage is reported in text, not digitized. — Results 3.3; Figure 4c and caption

Mean arterial pressure, heart rate and superior mesenteric artery blood flow: Blinded hemodynamics; mean ± SD; figure n = 7–9 per group. Propranolol portal-pressure comparison labeled p = 0.08 in Figure 4c. — Results 3.3; Figure 4a,b,d; Discussion paragraph on combination

Cilofexor alone (n = 9) · Sections 2.3–2.4, 2.8, 2.10, 3.3; Figure 4

Propranolol comparator (n = 7) · Sections 2.3–2.4, 3.3; Figure 4

Cilofexor plus propranolol (n = 7) · Sections 2.3–2.4, 3.3; Figure 4; Discussion

Dose-ranging cilofexor in BALB/cJ Mdr2 knockout mice

Animal study · Male and female BALB/cJ Mdr2/Abcb4 knockout mice, gavage treatment from 6 weeks of age for 10 weeks; sexes pooled [3]

Daily gavage lowered hepatic hydroxyproline at all tested doses and PSR-positive area at 90 mg/kg. Serum AST, ALP and bilirubin improved at 90 mg/kg but ALT did not. Hepatic F4/80-positive area did not decrease. This model therefore supports endpoint-specific antifibrotic effects without uniform improvement in hepatocellular injury or macrophage staining.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Hepatic hydroxyproline and picrosirius-red-positive areadirection Hydroxyproline lower at 10, 30 and 90 mg/kg; PSR-positive area significantly lower at 90 mg/kg[3]
Serum AST, ALP, total bilirubin and ALTdirection AST, ALP and bilirubin lower at 90 mg/kg; ALT not significantly changed at any dose; 10 and 30 mg/kg did not improve these serum markers[3]
Hepatic F4/80-positive areadirection No reduction across cilofexor dose groups[3]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Every 24 hours
Treatment course
10 weeks, starting at 6 weeks of age
Vehicle
0.5% carboxymethylcellulose and 1% ethanol in Tris buffer, pH 8
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Cilofexor 10, 30 or 90 mg/kg
10, 30 or 90 mg/kg; separate dose groups in one experiment
Vehicle-treated BALB/cJ knockout mice and WT referenceFibrosis-marker improvements were endpoint- and dose-dependent. ALT and F4/80 area did not significantly improve; higher-dose serum changes cannot be assigned to the lower doses.[3]
Cilofexor 10, 30 or 90 mg/kg
Model: Male and female BALB/cJ Mdr2/Abcb4 knockout mice, gavage treatment from 6 weeks of age for 10 weeks; sexes pooled
Reported limits: No sex-specific efficacy estimates; sexes combined. Form, lot and purity not established in retrieved methods.
Methods and source locations

Compound reported in the paper: Cilofexor; Compound label in the paper: CILO; GS-9674

Compound-level BALB/cJ knockout mouse findings; no Adooq lot or dose equivalence across studies.

Materials and methods; Figures 2–4 and corresponding Results

Hepatic hydroxyproline and picrosirius-red-positive area: Biochemical hydroxyproline normalized to liver weight and histological PSR quantification; mean ± SD; n = 15 per group as specified by Figure 2/3 captions; one-way ANOVA. — Figure 3A–B and caption; Materials, Liver histology and biochemical analysis

Serum AST, ALP, total bilirubin and ALT: Serum enzymatic assays; mean ± SD; n = 15 per group; one-way ANOVA. No plot-derived numerical estimates. — Figure 2; Results, BALB/cJ subsection

Hepatic F4/80-positive area: F4/80 immunostaining; individual mouse points shown; mean ± SD; Figure 4A. — Figure 4A and caption; corresponding Results

Cilofexor 10, 30 or 90 mg/kg · Materials, Animals experiments; Figures 2–4

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 1418274-28-8
Applications FXR agonist
Formula C28H22Cl3N3O5
Molecular Weight 586.85
Synonyms GS-9674
SMILES
ClC1=C(C2(CN(C3=CC(C(O)=O)=CC=N3)C2)O)C=CC(OCC4=C(C5CC5)ON=C4C(C(Cl)=CC=C6)=C6Cl)=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Cilofexor Research References

  1. [1] Klindt C, Truong JK, Bennett AL, et al. Hepatic bile acid accretion correlates with cholestatic liver injury and therapeutic response in Cyp2c70 knockout mice with a humanized bile acid composition American journal of physiology. Gastrointestinal and liver physiology (2024). PMID: 39350733 DOI: 10.1152/ajpgi.00129.2024 Source material
  2. [2] Schwabl P, Hambruch E, Budas GR, et al. The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model Biomedicines (2021). PMID: 33435509 DOI: 10.3390/biomedicines9010060 Source material
  3. [3] Fuchs CD, Sroda N, Scharnagl H, et al. Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in the Mdr2-/- mouse model of sclerosing cholangitis JHEP Reports (2023). PMID: 37841639 DOI: 10.1016/j.jhepr.2023.100874 Source material

Publications

1 publication citing this product

  1. Caroline Klindt, .et al. , Am J Physiol Gastrointest Liver Physiol, 2024, Oct 1 PMID: 39350733

Added to your cart

View Cart Checkout
Loading...